Kyntra Bio
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
350 Bay 06009 St Ste 100, San Francisco,...Website
www.kyntrabio.comRevenue
$5.9 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Kyntra Bio
Kyntra Bio, Inc. (formerly FibroGen, Inc.) is a U.S. biopharmaceutical company that discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It focuses on developing drug candidates for conditions such as anemia, cancer, and other diseases with high clinical impact potential. The company rebranded as Kyntra Bio to reflect a sharpened strategic focus on high-impact therapies.Explore more
Popular SearchesKyntra Bio IncSIC Code 28,283NAICS Code 32,325Show moreKyntra Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kyntra Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Kyntra Bio
Check out if Kyntra Bio is spiking on competitors!
Website visits: Recent activity has been detected on your website
Kyntra Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Kyntra Bio had a recent Job posting/layoffs
Check if Kyntra Bio has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Kyntra Bio launches new products
Funding: Get notified immidiatlly once Kyntra Bio has new funding data
Earning: See what the market has to say on Kyntra Bio recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Kyntra Bio as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Kyntra Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Kyntra Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Kyntra Bio.
Kyntra Bio News & Media
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
SAN FRANCISCO, May 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the first quarter 2026 and provided an update on the company’s recent developments.Kyntra Bio to Report First Quarter 2026 Financial Results
SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce first quarter 2026 financial results on Monday, May 11 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference
SAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the Company will present at the 25th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026.Kyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call Transcript
Kyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call March 16, 2026 5:00 PM EDTCompany ParticipantsThane Wettig - CEO & DirectorDavid DeLucia - Senior VP &...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Kyntra Bio
Sign Up For FreeTo access detailed company insights
Kyntra Bio, Inc. (formerly FibroGen, Inc.) is a U.S. biopharmaceutical company that discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It focuses on developing drug candidates for conditions such as anemia, cancer, and other diseases with high clinical impact potential. The company rebranded as Kyntra Bio to... Read More
